Pulsenmore Ltd(PLSM) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.44 | Insider Own | 41.37% | Shs Outstand | 6.5M | Perf Week | -5.27% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 4.7M | Perf Month | -25.17% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | - | Inst Own | 5.93% | Short Float | 0.06% | Perf Quarter | -52.5% |
| Income | -0.01B | P/S | 1.02 | EPS this Y | - | Inst Trans | 1.56% | Short Ratio | 0.04 | Perf Half Y | -51.37% |
| Sales | 0.01B | P/B | 0.66 | EPS next 5Y | - | ROA | -26.98% | Short Interest | 0.00M | Perf YTD | -82.66% |
| Book/sh | 2.49 | P/C | 0.56 | EPS past 3/5Y | 13.21% -1.94% | ROE | -48.74% | 52W High | -87.36% ($12.97) | Perf Year | - |
| Cash/sh | 2.92 | P/FCF | - | Sales past 3/5Y | 14.32% - | ROIC | -57.23% | 52W Low | 4.38% ($1.57) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 24.28% | Gross Margin | 81.24% | Volatility(W/M) | 9.76% 9.11% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 0.1 | Sales Y/Y TTM | 406.71% | Oper. Margin | -33.2% | ATR (14) | 0.19 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.69 | EPS Q/Q | -77.35% | Profit Margin | -72.48% | RSI (14) | 30.72 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.84 | Sales Q/Q | 80.08% | SMA20 | -10.39% ($1.83) | Beta | - | Target Price | - |
| Payout | - | Debt/Eq | 0.71 | Earnings | 2026/8/31 | SMA50 | -26.04% ($2.22) | Rel Volume | 0.19 | Prev Close | $1.67 |
| Employees | 63 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | - | SMA200 | -55.89% ($3.72) | Avg Volume(3M) | 0.06M | Price | $1.64 |
| IPO | 2026/1/21 | Option/Short | No/Yes | Trades | 53 | Volume | 11,451 | Change | -1.87% |
🤰 PulseNmore is an Israel-based company specializing in <strong>home-use ultrasound</strong> devices, developing and selling a prenatal care platform that allows expectant mothers to easily perform ultrasound scans at home, with remote interpretation by medical professionals. The company has secured FDA De Novo approval and European CE MDR certification, and has partnered with Israel's largest HMO, <strong>Clalit</strong>, as well as Sheba Medical Center, among others, accumulating hundreds of thousands of scans. It is a small-cap stock listed on the Nasdaq and the Tel Aviv Stock Exchange.
Over the past 1 year, on the lower side
87% below its 1-year high.
Traded less than usual. That is 19% of its average volume.
PLSM has a sound balance sheet but weak earning power
Of every $100 in sales, $33.20 is lost.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $102. Peers typically go for $145.
Tap to view numbers
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 5.9%.
Tap to view numbers
It ranks #114 of 140 in the industry
Based on market cap of $13M.
HSCS#113 HeartSciences Inc $15M PER - PLSM#114 Pulsenmore Ltd $13M PER - 
CTSO#115 Cytosorbents Corp $13M PER - 
SINT#116 SINTX Technologies Inc $13M PER - 
IRIX#117 IRIDEX Corp $13M PER - 
FAQ
What kind of company is PLSM?
PLSM belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of PLSM?
The market cap of PLSM is approximately $13M, ranking 5,342 within its sector.
What is the 52-week high and low for PLSM?
PLSM has recorded a 52-week high of $12.97 and a low of $1.57.
